You just read:

Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing

News provided by

Sangamo BioSciences, Inc.

06 Sep, 2016, 07:00 ET